AstraZeneca PLC vs AXA SA: Strategic Comparison

This in-depth comparison examines AstraZeneca PLC and AXA SA across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AstraZeneca PLC on its own, evaluating AXA SA, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AstraZeneca PLC and AXA SA is widest.

On the headline numbers, AstraZeneca PLC reports annual revenue of $58.7B against ~$131.1B for AXA SA, while their respective market capitalizations stand at $254.6B and $90.3B. AstraZeneca PLC is headquartered in United Kingdom and AXA SA in France, and those different home markets shape how each company competes.

AstraZeneca PLC: AstraZeneca is a British-Swedish biopharmaceutical company best known to the public for the COVID-19 vaccine it developed with the University of Oxford, but most of its revenue comes from medicines for cancer, cardiovascular and metabolic disease, respiratory and immune conditions, and rare diseases. It is headquartered on the Cambridge Biomedical Campus in England and runs strategic research centres in the UK, Sweden, the United States and China; the Beijing centre announced in March 2025 was its sixth.

AXA SA: AXA SA is a Paris-based insurance group and one of the largest insurers in the world by revenue. It says it employs 156,000 people serving more than 92 million clients in 52 countries, and reported gross written premiums and other revenues of ~$131 billion (EUR 116 billion) for 2025. The group writes motor, home, commercial property, liability and specialty cover, life and savings contracts and health insurance, and manages the reserves backing those policies. Property and casualty is the largest business at ~$65.5 billion (EUR 58 billion) of 2025 premiums, ahead of life at ~$42.4 billion (EUR 37.5 billion) and health at ~$21.5 billion (EUR 19 billion).

AstraZeneca PLC and AXA SA pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AstraZeneca PLC and AXA SA.

AstraZeneca PLC business model: AstraZeneca discovers, develops and sells prescription medicines, and the economics turn on patent-protected pricing funded by heavy research spending. It invested $14.2 billion in research and development in 2025, about a quarter of Total Revenue, and reported gross profit of $48.1 billion on cost of sales of $10.6 billion. Because most drug candidates fail, the company supplements internal discovery with licensing and acquisitions, from the $39 billion Alexion deal to the Daiichi Sankyo antibody-drug conjugate alliance, and shares development costs and profits with partners including Daiichi Sankyo, Amgen and Merck.

AXA SA business model: AXA collects premiums across three businesses: property and casualty (motor, home, commercial property, liability and specialty risks written through AXA XL), life and savings (protection, general account savings and unit-linked contracts), and health (individual cover and employee benefits). In 2025 property and casualty premiums reached ~$65.5 billion (EUR 58 billion) and life and health premiums ~$63.8 billion (EUR 56.5 billion). Policies are sold through tied agents, brokers, bancassurance partners and direct digital channels. The group also earns investment income on the reserves it holds before claims are paid. Since selling AXA Investment Managers to BNP Paribas Cardif on July 1, 2025, AXA no longer runs a third-party asset manager and has BNP Paribas manage a large part of its own assets under a long-term agreement.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AstraZeneca PLC stack up against those of AXA SA.

AstraZeneca PLC competitive advantage: AstraZeneca's main advantage is the depth of its oncology portfolio and the Phase III evidence behind it. Tagrisso, Imfinzi, Enhertu, Lynparza and Calquence each rest on trials that changed treatment practice, and the company had more than 100 Phase III studies running at the end of 2025 after 16 positive Phase III readouts during the year. Scale matters too: $58.7 billion of Total Revenue and $14.2 billion of annual R&D spending let it fund late-stage trials that smaller biotechs cannot, which is why partners such as Daiichi Sankyo and Amgen co-develop medicines with it. Its commercial reach in emerging markets, where China alone is about 12% of revenue, is wider than that of most US-based rivals.

AXA SA competitive advantage: AXA's main advantage is a diversified risk pool. Writing motor, home, commercial property, liability, health and life cover in 52 countries lets one bad year in a single market or line be absorbed elsewhere: in 2025 growth in health and European commercial lines offset pressure in other portfolios. Its balance sheet supports that spread, with a Solvency II ratio of 224% at the end of 2025. The 2018 purchase of XL Group added Lloyd's market access and large-corporate broker relationships that regional insurers cannot match, and the AXA brand supports distribution through tied agents, brokers and bancassurance partners across Europe and Asia.

Future prospects matter as much as current results. The growth strategies below explain how AstraZeneca PLC and AXA SA each plan to expand from here.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.

AXA SA growth strategy: AXA grows mostly organically in insurance lines it can price, supplemented by bolt-on deals: Laya Healthcare in Ireland and GACM España in 2023, and a 51% stake in the Italian direct insurer Prima announced in 2025 for ~$565 million (EUR 500 million). The bigger strategic move has been simplification. AXA listed and sold down its United States life business as Equitable Holdings from 2018, bought XL Group to build commercial lines, and completed the sale of AXA Investment Managers to BNP Paribas Cardif on July 1, 2025, using part of the proceeds for a ~$4.29 billion (EUR 3.8 billion) buyback. Management also reports efficiency gains from automation and artificial intelligence in claims and service work.

A closer look at the financial trajectory of AstraZeneca PLC and AXA SA rounds out the comparison.

AstraZeneca PLC: AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021.

AXA SA: AXA's results combine large, slow-moving premium income with investment income on the reserves it holds. In 2025 gross written premiums and other revenues rose 6% to ~$131 billion (EUR 116 billion), underlying earnings rose 6% to ~$9.49 billion (EUR 8.4 billion), underlying earnings per share rose 8% to EUR 3.86 and net income rose to ~$11.1 billion (EUR 9.80 billion), helped by the gain on the sale of AXA Investment Managers. The property and casualty combined ratio improved 0.3 points to 90.6%, so underwriting itself was profitable before investment income. The Solvency II ratio ended 2025 at 224%, and 215% on January 1, 2026 once capital instruments under Solvency II transitional measures stopped qualifying. AXA proposed a dividend of EUR 2.32 per share for 2025, up 8%, alongside an annual buyback of up to $1.41 billion (EUR 1.25 billion).